Pancreatic Cancer Research

ResearcherChangzhou No.2 People's HospitalNo recent work listed

Hanyu Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8117-6600; OpenAlex author ID A5102587076. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2019: 3 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 5

  1. Aspirin increases the efficacy of gemcitabine in pancreatic cancer by modulating the PI3K/AKT/mTOR signaling pathway and reversing epithelial‑mesenchymal trans… Co-author DOI 10.3892/ol.2023.13687↗
  2. Aspirin Regulates Gemcitabine Resistance in Pancreatic Cancer via Inhibiting the PI3K/Akt/mTOR Signaling Pathway and Reversing Epithelial-mesenchymal Transition Co-author DOI 10.21203/rs.3.rs-818856/v1↗
  3. The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction. Co-author DOI 10.1002/cam4.1988↗
  4. Significance of MUC2 gene methylation detection in pancreatic cancer diagnosis. Co-author DOI 10.1016/j.pan.2019.09.012↗
  5. A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.30561↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kequn Xu · 5 shared papers, 2019–2023 · strength 0.68
  2. Feifei Wei · 2 shared papers, 2019–2021 · strength 0.23
  3. Hua Jiang · 2 shared papers, 2019 · strength 0.18
  4. Xuguang Yang · 2 shared papers, 2019 · strength 0.18
  5. Junjie Hang · 2 shared papers, 2019 · strength 0.18
  6. Lixia Wu · 2 shared papers, 2019 · strength 0.18
  7. Yun Xiao · 1 shared paper, 2021 · strength 0.13
  8. Yuqing Cheng · 1 shared paper, 2019 · strength 0.10
  9. Siyuan Zhou · 1 shared paper, 2019 · strength 0.09
  10. Junjie Huang · 1 shared paper, 2019 · strength 0.09
  11. Yuli Lin · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.